[go: up one dir, main page]

WO2004080387A3 - Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins - Google Patents

Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins Download PDF

Info

Publication number
WO2004080387A3
WO2004080387A3 PCT/US2004/003642 US2004003642W WO2004080387A3 WO 2004080387 A3 WO2004080387 A3 WO 2004080387A3 US 2004003642 W US2004003642 W US 2004003642W WO 2004080387 A3 WO2004080387 A3 WO 2004080387A3
Authority
WO
WIPO (PCT)
Prior art keywords
ligand
antigenic molecule
fusion proteins
immunogenic
molecule complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/003642
Other languages
French (fr)
Other versions
WO2004080387A2 (en
Inventor
Pramod K Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut Health Center
Original Assignee
University of Connecticut Health Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut Health Center filed Critical University of Connecticut Health Center
Priority to EP04737304A priority Critical patent/EP1594443A2/en
Priority to AU2004220627A priority patent/AU2004220627A1/en
Priority to CA002515286A priority patent/CA2515286A1/en
Publication of WO2004080387A2 publication Critical patent/WO2004080387A2/en
Anticipated expiration legal-status Critical
Publication of WO2004080387A3 publication Critical patent/WO2004080387A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to complexes and fusion proteins comprising a CD91 ligand and an antigenic molecule, for use in the treatment or prevention of a disease. The invention specifically provides complexes comprising a CD91 ligand noncovalently boundto, or alternatively crosslinked to, an antigenic molecule. The invention also specifically provides fusion proteins comprising a CD91 ligand fused via a peptide bond to an antigenic molecule.
PCT/US2004/003642 2003-02-04 2004-02-04 Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins Ceased WO2004080387A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04737304A EP1594443A2 (en) 2003-02-04 2004-02-04 Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins
AU2004220627A AU2004220627A1 (en) 2003-02-04 2004-02-04 Immunogenic CD19 ligand-antigenic molecule complexes and fusion proteins
CA002515286A CA2515286A1 (en) 2003-02-04 2004-02-04 Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44476903P 2003-02-04 2003-02-04
US60/444,769 2003-02-04

Publications (2)

Publication Number Publication Date
WO2004080387A2 WO2004080387A2 (en) 2004-09-23
WO2004080387A3 true WO2004080387A3 (en) 2009-03-26

Family

ID=32990604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/003642 Ceased WO2004080387A2 (en) 2003-02-04 2004-02-04 Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins

Country Status (4)

Country Link
EP (1) EP1594443A2 (en)
AU (1) AU2004220627A1 (en)
CA (1) CA2515286A1 (en)
WO (1) WO2004080387A2 (en)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BINDER R.J. ET AL.: "Naturally formed or artificially reconstituted non-covalent alpha2- macroglobulin peptide complexes elicit CD91-dependent cellular immunity.", CANCER IMMUNITY., vol. 2, 18 December 2002 (2002-12-18), pages 1 - 9 *
NIELSEN M.S. ET AL.: "Analysis of Ligand Binding to the alpha2-Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 40, 6 October 1995 (1995-10-06), pages 23713 - 23719 *

Also Published As

Publication number Publication date
EP1594443A2 (en) 2005-11-16
CA2515286A1 (en) 2004-09-23
AU2004220627A1 (en) 2004-09-23
WO2004080387A2 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
WO2002062377A3 (en) Combined use of factor vii polypeptides and factor viii polypeptides
WO2004069206A3 (en) Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
WO2004010957A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
MXPA02010787A (en) Modified peptides as therapeutic agents.
WO2003057134A3 (en) Specific binding agents of human angiopoietin-2
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
SI1180121T1 (en) Long lasting insulinotropic peptides
WO2000078344A8 (en) Prion protein peptides and uses thereof
WO2003090686A3 (en) Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
HK1052301A1 (en) Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
IL161352A0 (en) Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
AU2210402A (en) Photochemical internalization for virus-mediated molecule delivery into the cyosol
MXPA03008739A (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours.
WO2005020936A3 (en) Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
WO2005120558A3 (en) Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
WO2006060021A3 (en) Bifunctional fusion proteins containing the flt3 ligand
ZA200400313B (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
WO2005042566A3 (en) Antiangiogenicpeptides for treating or preventing endometriosis
WO2005009366A3 (en) Restoring vascular function
WO2005001048A3 (en) Preparation and application of anti-tumor bifunctional fusion proteins
WO2004069207A3 (en) Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
WO2004080387A3 (en) Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006508696

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2515286

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2004220627

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004220627

Country of ref document: AU

Date of ref document: 20040204

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2004737304

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004220627

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004737304

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP